BidaskClub Downgrades Dermira (NASDAQ:DERM) to Sell

Dermira (NASDAQ:DERM) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Tuesday, BidAskClub reports.

Other research analysts have also issued reports about the company. Needham & Company LLC reiterated a “buy” rating and set a $20.00 target price on shares of Iterum Therapeutics in a report on Monday, March 25th. Cantor Fitzgerald reiterated a “hold” rating and set a $8.00 target price on shares of Pacific Biosciences of California in a report on Friday, May 3rd. HC Wainwright set a $31.00 target price on Kura Oncology and gave the stock a “buy” rating in a report on Wednesday, May 8th. Zacks Investment Research lowered Haynes International from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th. Finally, Citigroup set a $68.00 target price on Colgate-Palmolive and gave the stock a “hold” rating in a report on Tuesday, March 19th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. Dermira presently has a consensus rating of “Buy” and a consensus target price of $17.97.

NASDAQ:DERM opened at $8.57 on Tuesday. Dermira has a 12-month low of $6.00 and a 12-month high of $15.48. The company has a debt-to-equity ratio of 4.36, a current ratio of 7.13 and a quick ratio of 6.92. The company has a market cap of $465.30 million, a price-to-earnings ratio of -1.64 and a beta of 1.34. The business has a fifty day moving average of $9.38.

Dermira (NASDAQ:DERM) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by ($0.39). Dermira had a negative return on equity of 391.86% and a negative net margin of 510.47%. The company had revenue of $2.45 million during the quarter, compared to the consensus estimate of $2.63 million. On average, sell-side analysts predict that Dermira will post -5.2 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in DERM. Metropolitan Life Insurance Co. NY raised its stake in shares of Dermira by 356.7% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 12,912 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 10,085 shares during the period. Jane Street Group LLC acquired a new stake in shares of Dermira in the 4th quarter valued at about $95,000. BNP Paribas Arbitrage SA raised its stake in shares of Dermira by 48,273.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,256 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 7,241 shares during the period. Fox Run Management L.L.C. acquired a new stake in shares of Dermira in the 2nd quarter valued at about $120,000. Finally, Nisa Investment Advisors LLC raised its stake in shares of Dermira by 2,500.0% in the 1st quarter. Nisa Investment Advisors LLC now owns 10,400 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 10,000 shares during the period. 93.92% of the stock is currently owned by hedge funds and other institutional investors.

About Dermira

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Further Reading: Trading Options- What is a Strangle?

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.